Gland Pharma open for subscription; why should you subscribe?

Promoters in the company - Fosun Singapore and Shanghai Fosun Pharma - will reduce their shareholding from 74% to around 58 percent. Hyderabad-based injectable-focus-med drugmaker Gland Pharma opened its public issue for subscription on November 9 at Rs 1,490-1,500 per share with the issue band.

from Business News https://ift.tt/3ka0jFG
WWW.ATGNEWS.COM